Proteus Granted U.S. Patent on Gene Shuffling Technology
News Oct 12, 2005
Proteus has announced that it has been granted U.S. Patent No. 6,951,719 for L-Shuffling™, a gene shuffling technology developed by Proteus to generate and optimize proteins for commercial product applications.
This L-Shuffling™ recombination-based protein engineering technology dramatically accelerates the development of new or improved products and processes.
L-Shuffling™'s growing list of applications include developing therapeutic proteins, industrial biocatalysts and agricultural traits optimization.
The new patent broadly covers Proteus in vitro gene shuffling recombination methods in a variety of embodiments, and contains multiple claims covering ligation-mediated in vitro recombination methods.
“Getting the protein you have been dreaming of is what L-Shuffling™ provides,” said Daniel Dupret, President and CEO of Proteus. “The issuance of this new patent reinforces Proteus leadership in this field of biotechnology.”
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE